Dosing Parameters
Interactive Modeler
Target Indication / Condition
Select to load clinical benchmark
Alzheimer's
ADHD
Skin Rejuvenation
Macular Decline
Delivered Surface Fluence
45.0 J/cm²
Energy density formula
Depth Attenuation Delivery
1.35 J/cm²
Beer-Lambert modeled
Mitochondrial Activation
High
Cytochrome C Oxidase peak
Recommended λ
670 nm
Literature standard
Reset to Default
Protocol Exported
Spectral Efficacy & Cellular Mechanism
Emerging / Pre-clinical & Small Trials
Cytochrome C Oxidase (CCO) Absorption Spectrum vs. Current Wavelength (670nm )
Red to Near-IR Window
Transcranial 670nm near-infrared light targets mitochondrial dysfunction and microglial activation in neural tissue.
Evaluation Parameter
Current Observation
Clinical Reference Standard
Condition Category
Alzheimer's Disease (Neurological)
Central Nervous System / Neurodegeneration
Evidence Tier
Emerging / Pre-clinical & Small Trials
Human pilot trials, fMRI & rodent models
Target Cytochrome C Activation
High (Cytochrome c oxidase activation)
660–680nm & 810–830nm absorption peaks
Optical Penetration Depth
Target: 10 mm (Transcranial)
Scalp & skull transmission: ~1% to 5%
Reported Biomarkers
Amyloid-β clearance, ATP synthesis, BDNF upregulation
Microglial phenotypic shift (M1 to M2)
// Structured Photobiomodulation Protocol
Condition: Alzheimer's Disease (Neurological)
Wavelength: 670 nm (Target CCO excitation)
Irradiance: 50 mW/cm² | Duration: 15 min
Calculated Energy Density: 45.0 J/cm²
Mitochondrial Absorption Score: High (Cytochrome c oxidase activation)
Evidence Tier: Emerging / Pre-clinical & Small Trials
Status: Transcranial 670nm near-infrared light targets mitochondrial dysfunction and microglial activation in neural tissue.
Research Context & Clinical Disclaimers: Photobiomodulation (PBM) relies on photons being absorbed by endogenous chromophores—primarily Cytochrome c Oxidase (Unit IV in mitochondrial respiratory electron transport chain). Light absorption alters mitochondrial membrane potentials, increases ATP production, and modulates reactive oxygen species (ROS) signaling cascades. While dermatology (wound healing, collagen remodeling) and ophthalmology (macular decline via 670nm photoreceptor rescue) boast double-blind trials, neurological applications (Alzheimer’s, Parkinson’s, ADHD) remain an active investigative frontier with variable skull attenuation barriers. Data presented here illustrates modeled biophysical calculations and published academic research benchmarks, not individual medical advice.